About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Schools
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Scientometrics
Avg Impact Factor
h-index
g-index
★★
Articles
★★★
Articles
exaly
›
Institutions
›
Alvin J. Siteman Cancer Center
›
Top Articles
Alvin J. Siteman Cancer Center
United States of America
(siteman.wustl.edu)
1.3K
(top 11%)
articles
80.3K
(top 6%)
citations
575
(top 7%)
★★
articles
64
(top 4%)
★★★
articles
4.7
(top 4%)
Avg IF
122
(top 5%)
H-Index
262
(top 4%)
G-Index
375
journals
Most Cited Articles of Alvin J. Siteman Cancer Center in 2018
Title
Journal
Year
Citations
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Cell
2018
1.1K
Comprehensive Characterization of Cancer Driver Genes and Mutations
Cell
2018
854
DGIdb 3.0: a redesign and expansion of the drug-gene interaction database
Nucleic Acids Research
2018
414
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Cell Reports
2018
405
Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Cell
2018
350
Pathogenic Germline Variants in 10,389 Adult Cancers
Cell
2018
342
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Cell Systems
2018
320
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Cell Reports
2018
235
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
European Journal of Cancer
2018
179
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Cell
2018
166
Systematic Analysis of Splice-Site-Creating Mutations in Cancer
Cell Reports
2018
121
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Journal of Clinical Oncology
2018
120
Systematic Functional Annotation of Somatic Mutations in Cancer
Cancer Cell
2018
114
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Blood
2018
83
Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Cancer Discovery
2018
78
Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma
European Urology
2018
73
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses
Cancer Cell
2018
67
Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision
Journal of Pathology
2018
66
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma
Cancer Immunology Research
2018
66
The prognostic effects of somatic mutations in ER-positive breast cancer
Nature Communications
2018
51
Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis
Clinical Breast Cancer
2018
48
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
Cell Reports
2018
43
Metal–Organic Framework Encapsulation for Biospecimen Preservation
Chemistry of Materials
2018
41
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Blood
2018
39
Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study
Blood
2018
38
site/software ©
exaly
; All materials licenced under
CC by-SA
.